Birmingham Capital Management Co. Inc. AL Has $4.85 Million Position in Johnson & Johnson $JNJ

Key Points

• Birmingham Capital Management Co. Inc. AL decreased its holdings in Johnson & Johnson by 18.1%, owning 31,748 shares valued at approximately $4.85 million, making it the firm's 12th largest investment.
• Johnson & Johnson recently reported a quarterly earnings EPS of $2.26 and announced a quarterly dividend of $1.30 per share, representing an annual yield of 2.7%.
• Several analysts have increased their price targets for Johnson & Johnson shares, with the consensus price target now at $200.06 and a majority rating the stock as a Moderate Buy.

Birmingham Capital Management Co. Inc. AL reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,748 shares of the company's stock after selling 7,029 shares during the quarter. Johnson & Johnson accounts for 2.1% of Birmingham Capital Management Co. Inc. AL's investment portfolio, making the stock its 12th biggest holding. Birmingham Capital Management Co. Inc. AL's holdings in Johnson & Johnson were worth $4,849,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Swan Global Investments LLC raised its stake in Johnson & Johnson by 21.3% during the 2nd quarter. Swan Global Investments LLC now owns 2,142 shares of the company's stock valued at $327,000 after purchasing an additional 376 shares during the period. Uhlmann Price Securities LLC grew its holdings in shares of Johnson & Johnson by 7.3% during the 2nd quarter. Uhlmann Price Securities LLC now owns 5,335 shares of the company's stock valued at $815,000 after acquiring an additional 362 shares in the last quarter. Calamos Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Calamos Wealth Management LLC now owns 120,131 shares of the company's stock valued at $18,350,000 after acquiring an additional 3,737 shares in the last quarter. Chicago Partners Investment Group LLC grew its holdings in shares of Johnson & Johnson by 9.2% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 22,557 shares of the company's stock valued at $3,814,000 after acquiring an additional 1,899 shares in the last quarter. Finally, Sigma Investment Counselors Inc. grew its holdings in shares of Johnson & Johnson by 2.6% during the 2nd quarter. Sigma Investment Counselors Inc. now owns 10,236 shares of the company's stock valued at $1,564,000 after acquiring an additional 264 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.3%

JNJ stock opened at $193.78 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The company has a 50-day moving average of $180.89 and a two-hundred day moving average of $165.18. The stock has a market capitalization of $466.68 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion during the quarter. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. Raymond James Financial boosted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an "outperform" rating in a report on Wednesday, October 15th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, HSBC upped their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a "buy" rating in a report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $200.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.